Johnson & Johnson’s schizophrenia drug Risperdal at Skenderian Apothecary in Cambridge, Massachusetts, on Jan. 23, 2007. Photo: JB Reed/Bloomberg News.
The Philadelphia jury deliberating in the first punitive damages trial over the drug Risperdal needs to use its verdict to send pharmaceutical company Johnson & Johnson a message, an attorney representing a man injured by the medication said Tuesday.
“What happens today will have long-reaching consequences, in Philadelphia, in the nation, and, literally, from this little room in 275 [of Philadelphia City Hall], around the world,” Kline & Specter attorney Thomas R. Kline told the jury, which has presided over the trial since mid-September. “We’ve tried for years, collectively, to change their behavior, but you 12 individuals, as a jury speaking as one, have that power.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
